வாழ்க்கை அறிவியல் அக்கறை போஸ்டன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from வாழ்க்கை அறிவியல் அக்கறை போஸ்டன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In வாழ்க்கை அறிவியல் அக்கறை போஸ்டன் Today - Breaking & Trending Today

Quench Bio Winds Down Operations Following 'Successful Failure'


The company announced its decision Tuesday in a
series of posts on Twitter. In what Quench Bio called a “successful failure,” the company said its drug target proved undruggable to its efforts.
Quench was developing an approach to inhibit Gasdermin D, which was believed to be a key target at the core of multiple inflammatory cell death pathways, including pyroptosis and NETosis. When pyroptosis or NETosis pathways are activated, gasdermin is processed and forms lytic pores on the cell membrane, allowing release of inflammatory cytokines, alarmins, DNA and NETs. Pyroptosis and NETosis are associated with numerous inflammatory diseases, including rheumatoid arthritis, lupus, multiple sclerosis and nonalcoholic steatohepatitis (NASH), as well as other diseases. ....

United States , United Kingdom , Arix Biosciences , Atlas Venture , Life Sciences Cares Boston , Quench Bio , Atlas Ventures , Abbvie Ventures , Quench Bio Winds Down Operations Following Successful Failure , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , அட்லஸ் துணிகர , வாழ்க்கை அறிவியல் அக்கறை போஸ்டன் , தணிக்கவும் உயிர் , அட்லஸ் முயற்சிகள் , தணிக்கவும் உயிர் காற்று கீழ் செயல்பாடுகள் பின்வருமாறு வெற்றிகரமாக தோல்வி ,

Quench Bio hit by 'successful failure,' winds down ops in Twitter thread as tech sold off at auction


(GH01/ iStock)
Quench Bio’s short journey has come to an end after the biotech startup found that its target was simply undruggable.
The Cambridge, Massachusetts-based biotech had focused on blocking the gasdermin D protein with oral inhibitors to treat inflammatory diseases and had attempted to seek out a potent, selective chemical series to progress by the first quarter of 2021.
It has not, however, managed to hit that goal, and, with credit to the company, it is not trying to spin out this failure, but says it now simply recommends “to wind down and return capital to investors.” It raised $50 million last year from the likes of RA Capital, AbbVie Ventures, Atlas Venture and Arix Bioscience, and was a 2020 Fierce 15 winner. ....

United States , United Kingdom , Mike Nolan , Arix Bioscience , Eli Lilly , Mark Tebbe , Samantha Truex , Paraza Pharma , Iain Kilty , Atlas Venture , Clinical Collaborative Research Organization , Bristol Myers Squibb , Quench Bio , Abbvie Ventures , Life Science Cares Boston , Padlock Therapeutics , Chief Technology Officer Mark Tebbe , Senior Director , Biology Mike Nolan , Big Pharma , Scientific Officer Iain Kilty , Fierce 15 , Failed Drug Program , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , மைக் நோலன் ,